Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by University Hospital, Angers.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Assistance Publique - Hôpitaux de Paris
Information provided by:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT00188019
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

September 12, 2005
September 12, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Evaluation Des méthodes De dépistage Du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement

Hereditary paraganglioma -due to SDH (SDHD, SDHB, SDHC) germline mutations- causes paragangliomas and pheochromocytomas. Presymptomatic genetic testing should be offered to all first-degree relatives if an SDH mutation is detected in an index case with paraganglioma or pheochromocytoma. The main objective of our national clinical research project is to test different screening methods to detect presymptomatic tumors in order to establish guidelines for the work-up and the follow-up of SDH mutation carriers.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Paraganglioma
  • Pheochromocytoma
Procedure: diagnosis methods
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria: identification of an SDH (SDHD, SDHD, SDHC) germline mutation

Both
6 Years and older
Not Provided
Contact: Anne-Paule Gimenez-Roqueplo, MD, PhD 33 1 56 09 38 81 anne-paule.gimenez@hop.egp.ap-hop-paris.fr
France
 
NCT00188019
PHRC 04-01
Not Provided
Not Provided
University Hospital, Angers
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Vincent Rohmer, MD University Angers Hospital
Principal Investigator: Anne-Paule Gimenez-Roqueplo, MD, PhD Paris-Descartes University, Européen Georges Pompidou Hospital, Assistance Publique des Hôpitaux de Paris
University Hospital, Angers
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP